Pantop%252525252525252525252525252525252525252525252525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion. ## Primary Indications * Gastroesophageal reflux disease (GERD) * Erosive esophagitis healing * Maintenance of healing of erosive esophagitis * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome) * Combination therapy for *Helicobacter pylori* eradication ## Adult Dosing * **GERD:** 40 mg orally once daily for up to 8 weeks. * **Erosive esophagitis healing:** 40 mg orally once daily for up to 8 weeks. May require up to 16 weeks in some patients. * **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily. * **Pathological hypersecretory conditions:** Starting dose 40 mg orally twice daily. Doses may be adjusted based on clinical response, typically up to 240 mg daily divided into two doses. * ***H. pylori* eradication:** 40 mg orally twice daily for 7-14 days in combination with antibiotics (e.g., amoxicillin and clarithromycin or clarithromycin and metronidazole). Intravenous (IV) dosing: * **GERD and erosive esophagitis healing:** 40 mg IV once daily. * **Pathological hypersecretory conditions:** 40 mg IV twice daily. Doses may be increased to 80 mg IV every 8 hours. Maximum oral dose: 240 mg/day. Maximum IV dose: 80 mg every 8 hours. ## Pediatric Dosing * **GERD and erosive esophagitis healing:** * Children 5 years and older: 40 mg orally once daily for up to 8 weeks. * Children 1 month to 5 years: 20 mg orally once daily for up to 8 weeks. * Children younger than 1 month: Safety and efficacy not established. IV dosing in pediatrics is generally based on body weight and is typically determined by specialist protocol. ## Dose Adjustments No dose adjustment is typically required for hepatic or renal impairment, although caution is advised in severe hepatic impairment. ## Contraindications * Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles. * Concomitant use with rilpivirine-containing products. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and rash. Long-term use of PPIs has been associated with an increased risk of *Clostridioides difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia. ## Key Drug Interactions * **CYP2C19 substrates:** Pantoprazole can increase plasma concentrations of drugs metabolized by CYP2C19 (e.g., clopidogrel, voriconazole). * **CYP3A4 substrates:** May affect absorption of drugs requiring gastric acid for absorption (e.g., ketoconazole, itraconazole, digoxin). * **Methotrexate:** PPIs may increase methotrexate levels. * **Rilpivirine:** Contraindicated due to increased risk of virologic failure. * **Ulipristal:** Reduced efficacy due to decreased absorption. ## Monitoring * Monitor for effectiveness in symptom relief. * Monitor electrolytes (magnesium, sodium, potassium) with prolonged therapy. * Monitor for signs and symptoms of *C. difficile* infection. * Monitor bone mineral density with long-term use, especially in patients at risk for osteoporosis. ## Clinical Pearls * Administer 30 minutes to 1 hour before meals. * For oral suspension, reconstitute with water and swirl. Do not chew or crush delayed-release granules. * IV administration: Reconstitute with sterile water and further dilute in normal saline or dextrose 5% injection. Infuse over 15 minutes. * Consider the potential for increased risk of fractures, *C. difficile* infection, and B12 deficiency with long-term use. *** **Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for definitive patient management decisions.